Get started
CVS HEALTH CORPORATIONCVS HEALTH CORPORATIONCVS HEALTH CORPORATION

CVS HEALTH CORPORATION

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

CVS trade ideas

CVS Health Corp | CVS | Long at $61.00NYSE:CVS Health Corp will need a revision to its business model in order to survive an ever-changing retail/pharmacy environment. However, with a P/E of 10x, debt-to-equity of less than 1x, growing cash flow, and dividend yield of 4.3%, the stock seems quite undervalued. Perhaps activist investors will soon step in, but if history repeats, there may be a nice bounce ahead as the price consolidates in the GETTEX:50S and low $60s. Thus, near its current price of $61, NYSE:CVS is in a personal buy zone. Target #1 = $66.00 Target #2 = $68.00 Target #3 = $75.00 Target #4 = $79.00
NYSE:CVSLong
by NicksAnalysis
CVS - CVS Health: If the stock drops a few points, I'll be buyiIf the stock drops a few points, I'll be buying very heavily... CVS and WBA are in the same sector. And both have been decimated. CVS, however, is doing better. And they're paying a dividend. Target, at least +10%. Trading at 70% below estimate of its fair value Earnings are forecast to grow 9% per year Earnings grew by 140% over the past year DIVIDEND = Pays a high and reliable dividend of 4.75% Trading at good value compared to peers and industry Analysts in good agreement that stock price will rise by 20%
NYSE:CVSLong
by Maximus20000
(CVS) Is an Intelligent Buy for Strategic InvestorsIn an ever-evolving healthcare landscape, CVS Health Corp. (NYSE: CVS) has established itself as a critical player, integrating retail, pharmacy services, and health insurance into a comprehensive healthcare solution. For investors who align with the sophisticated trading principles of DiamondTradingOfficial, CVS presents a compelling case for investment, driven by its robust fundamentals, strategic positioning, and favorable technical indicators. Integrated Healthcare Model and Strategic Moat CVS Health has transformed itself from a retail pharmacy chain into a diversified healthcare company with a broad range of services, including pharmacy benefit management, retail health clinics, and health insurance through its acquisition of Aetna. This integrated approach not only enhances the company’s revenue streams but also creates significant synergies across its business units. The company’s ability to offer end-to-end healthcare services establishes a formidable economic moat, making it difficult for competitors to match its comprehensive offerings. This strategic positioning is particularly relevant as the healthcare industry increasingly moves towards value-based care, where patient outcomes, rather than services rendered, drive compensation. CVS’s integrated model allows it to manage and coordinate patient care effectively, reduce costs, and improve health outcomes. This not only enhances the company’s competitive advantage but also positions it for sustainable long-term growth—an essential criterion for value investors. Strong Financial Performance and Undervaluation From a financial perspective, CVS Health has demonstrated consistent revenue growth and strong cash flow generation. The company’s diversified revenue streams provide stability, even in uncertain economic environments, while its focus on operational efficiency has helped maintain healthy profit margins. Despite these strengths, CVS’s stock is currently trading at a discount relative to its intrinsic value, making it an attractive investment for those seeking undervalued opportunities. A detailed discounted cash flow (DCF) analysis reveals that CVS Health’s future earnings potential, particularly from its growing healthcare services segment, is not fully reflected in its current stock price. This discrepancy between intrinsic value and market price provides a significant margin of safety, a principle that is central to both Warren Buffett’s value investing philosophy and the advanced trading strategies employed by DiamondTradingOfficial. Moreover, CVS’s price-to-earnings (P/E) ratio is well below the industry average, indicating that the stock is undervalued relative to its peers. This undervaluation, combined with the company’s strong fundamentals and strategic positioning, makes CVS Health an ideal candidate for long-term investment. Technical Indicators and Market Sentiment Advanced technical analysis also supports the case for CVS Health as a strategic buy. The stock has shown strong support levels in recent trading sessions, suggesting that it has found a stable base from which it can advance. Technical indicators such as the relative strength index (RSI) and moving average convergence divergence (MACD) point towards a potential upward momentum, making it an attractive entry point for investors. Furthermore, sentiment analysis reveals that institutional investors are increasingly bullish on CVS Health, recognizing the company’s strong fundamentals and growth potential. As healthcare continues to be a priority for consumers and governments alike, CVS is well-positioned to capitalize on this trend, driving future stock price appreciation. Conclusion CVS Health Corp. represents a compelling investment opportunity for strategic investors who prioritize value, growth, and advanced market analysis. The company’s integrated healthcare model, strong financial performance, and significant market undervaluation make it an ideal candidate for long-term investment. When analyzed through the lens of DiamondTradingOfficial’s advanced trading principles, CVS Health emerges as a stock with not only the potential for substantial appreciation but also the technical support for sustained upward momentum. For investors who adhere to the principles of value investing and advanced technical analysis, CVS Health is not just a good stock to buy—it is a strategic imperative in the healthcare sector.
NYSE:CVSLong
by DiamondTradingOfficial
CVS Health's Stock Tumbles 14% in Premarket trading on TuesdayCVS Health (NYSE: NYSE:CVS ) is grappling with significant challenges as its stock dropped 14% following the release of its second-quarter earnings report. Despite beating earnings expectations, the company has lowered its full-year profit outlook for the third consecutive quarter due to rising medical costs and operational shifts in its health insurance business.** Earnings and Revenue Overview CVS Health reported: - Earnings per share (EPS): $1.83 (adjusted) vs. $1.73 expected by analysts - Revenue: $91.23 billion vs. $91.5 billion expected The company achieved a net income of $1.77 billion, or $1.41 per share, down from $1.90 billion, or $1.48 per share, in the same quarter last year. Revenue grew by 2.6% year-over-year, driven by its pharmacy and insurance businesses. Profit Outlook and Executive Changes CVS Health has revised its 2024 adjusted earnings outlook to $6.40-$6.65 per share, down from the previous guidance of at least $7 per share. This adjustment reflects ongoing pressure from higher medical costs, particularly within its health insurance segment, which includes Aetna's Medicare Advantage, Medicaid, and other plans. In a significant management shift, Aetna President Brian Kane will leave the company immediately. CEO Karen Lynch will assume management responsibilities for the insurance unit, with CFO Thomas Cowhey and Chief Strategy Officer Katerina Guerraz assisting. Medical Costs and Industry Pressures The healthcare industry is experiencing increased medical costs as more Medicare Advantage patients return to hospitals for procedures delayed during the pandemic, such as joint and hip replacements. This trend is putting pressure on insurance companies like CVS Health, UnitedHealth Group, Humana, and Elevance Health. CVS Health's Medicare Advantage star ratings, which help Medicare patients compare health and drug plans, have also impacted its performance. The company's medical benefit ratio rose to 89.6% from 86.2% a year earlier, indicating higher medical expenses relative to premiums collected. Segment Performance - Insurance Segment: Generated $32.48 billion in revenue, up 21% year-over-year, but reported adjusted operating income of $938 million, below analyst expectations. - Health Services Segment: Generated $42.17 billion in revenue, down nearly 9% year-over-year. Processed 471.2 million pharmacy claims, down from 576.6 million a year ago. - Pharmacy and Consumer Wellness Division: Reported $29.84 billion in sales, up over 3% year-over-year, driven by increased prescription volume. However, the segment faced challenges from pharmacy reimbursement pressure, the introduction of new generic drugs, and decreased front-store volume. Strategic Adjustments CVS Health's pharmacy benefit manager (PBM) Caremark has seen declines due to losing key clients like Tyson Foods and Blue Shield of California. These losses reflect broader industry shifts towards transparency and cost reduction, with startups and government initiatives reshaping the landscape. Conclusion CVS Health's third-quarter earnings report underscores the significant challenges facing the company as it navigates rising medical costs and shifting industry dynamics. The lowered profit outlook and executive changes signal the need for strategic adjustments to address these pressures. As CVS Health adapts to these evolving conditions, the market will closely watch its efforts to stabilize and grow its diverse healthcare and retail operations.
NYSE:CVSShort
by DEXWireNews
Looking forward to CVS earnings. I can see CVS re-testing $55 and below if EPS comes in lower than what wall-street have price in. The only reason CVS have sell is the Pharmacy. Without that the store will be in chapter 13 bankruptcy. Amazon and Walmart have a better sales model to bring customers with cheaper drug prices to fill prescriptions. Looking at CVS on the 90 min timeframe I see we have a bounce at $56.65 if we can trend up we will break $57.69 and weekly open of $58.00 if earnings come in better than what Wall Street face price in we will see a re test of $58.80 and $60.75
NYSE:CVS
by EmpowermentAssets
CVS Long Swing 1H Conservative Trend TradeConservative Trend Trade + long balance + support level + 1/2 correction + ICE level + volumed 2Sp- + volumed bullish bars + unvolumed bearish bars Calculated affordable stop limit 25% 1 to 2 R/R 25% 1/2 of the daily range 25% Daily T1 level 25% Monthly 1/2 Daily context "+ long impulse + T2 level + support level + 1/2 correction + exhaustion volume below" Monthly context "- short impulse - unvolumed T1 + support level + biggest volume manipulation"
NYSE:CVSLong
by MishaSuvorov
CVS Health Corporation.The latest daily candlestick for CVS closed at $57.62, showing a minor gain of 1.28%. This movement is within a downtrend that started in early April, indicating a potential reversal or consolidation phase. The price is currently below the Ichimoku Cloud, suggesting bearish sentiment. However, a bullish crossover in the future could signal a potential trend reversal. Recent sector updates indicate mixed performance within healthcare stocks, which might impact CVS's stock in the short term. Positive news about strategic partnerships or earnings beats could provide a bullish catalyst, while regulatory challenges or earnings misses might weigh on the stock. CVS Health Corporation presents a mixed technical outlook with bearish momentum in the short term, yet potential for a bullish reversal. Traders should watch key support and resistance levels, along with monitoring volume and momentum indicators. Adapting to the latest market news and price action will be crucial for successful trading. Long Position: Entry Point: Consider entering a long position if the stock breaks above the immediate resistance at $59.45 (Pivot Point) with strong volume. Price Target: Aim for the next resistance at $61.68 (R1), with a potential to reach $67.31 (1-year price target). Stop Loss: Place a stop loss at $56.00 to manage downside risk. Short Position: Entry Point: Consider shorting if the stock falls below $56.83 (S1) with increasing volume. Price Target: Target the next support at $54.60 (S2), with a further downside to $49.76 (S3). Stop Loss: Set a stop loss at $58.00 to protect against a bullish reversal.
NYSE:CVS
by AxiomEx
CVS Health Plunges to 3-Year Low for the First TimeCVS Health Corporation ( NYSE:CVS ) stock price nosedives to its lowest level in three years, sending shockwaves through the market. The pharmacy chain's dismal performance in the first quarter of 2024 has rattled investors, with shares plummeting over 12% in premarket trading. The root cause of CVS Health's ( NYSE:CVS ) precipitous decline lies in its underwhelming Q1 earnings report, which fell short of market expectations on multiple fronts. Despite reporting a revenue of $88.44 billion, reflecting a 3.7% increase year-over-year, the figure failed to meet analysts' projections of $89.33 billion. Similarly, net income and diluted earnings per share (EPS) witnessed a significant decline compared to the previous year, with profits plummeting from $2.14 billion to $1.12 billion and EPS dropping from $1.65 to 88 cents. The downward spiral in CVS Health's fortunes can be attributed to a confluence of factors, chief among them being the slashing of its 2024 profit forecast. The company revised its adjusted EPS outlook downward to at least $7.00, down from the initial projection of at least $8.30. This drastic revision stems from mounting medical costs incurred by its insurance unit, driven by a surge in medical procedures that were postponed during the pandemic. As patients opt to undergo delayed treatments, CVS's insurance divisions are bearing the brunt, impacting the company's bottom line. While there was a faint glimmer of hope in the form of a slight sales increase in its pharmacy and consumer wellness division, with sales rising almost 3% to $28.73 billion, it failed to offset the broader disappointment. The challenges facing CVS Health ( NYSE:CVS ) extend beyond financial metrics, with the company grappling with workforce reductions and the loss of high-profile clients like Tyson Foods. The tumultuous environment has prompted NYSE:CVS to revise its full-year EPS guidance downward to at least $5.64, down from the previous estimate of at least $7.06. Despite the gloomy outlook, CEO Karen Lynch remains steadfast in her optimism about the company's long-term prospects. She asserts that while CVS faces near-term challenges, its fundamental strengths and strategic initiatives position it for sustained growth in the future.
NYSE:CVSShort
by DEXWireNews
Support And Resistance Lines Are Not Real: Prove Me WrongIn this video, I draw random lines on the chart to prove a point. I think we need to ask ourselves the following questions to become better traders: How will I define support and resistance consistently ? How will I use support and resistance in my trading? Do I need support and resistance in my trading? Is support and resistance a reliable measure for markets? Are the lines that I have been drawing for so long actually meaningful?
NYSE:CVSEducation
by JoeRodTrades
2